August 5, 2018
Atezolizumab Plus Chemotherapy Improves PFS for Triple-Negative Breast CancerBookmarkEmma Shtivelman, PhD
Excerpt from Healio:
“First-line atezolizumab plus nab-paclitaxel improved PFS compared with placebo among patients with metastatic or unresectable locally advanced triple-negative breast cancer, according to interim results from the IMpassion130 trial released by the manufacturer.
“Researchers observed prolonged PFS in both the intention-to-treat population and the PD-L1-positive population.”
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
April 4, 2017 Emma Shtivelman, PhD
By 2050, the number of deaths due to malignant melanoma in the U.S. could be three times lower than peak levels reached before 1960. Researchers presented the data behind this prediction at the 2017 European Cancer Congress in January. It is unclear how much of this anticipated decline in deaths can be attributed to the availability of new, effective treatments. However, it is obvious… Read more »
August 8, 2016 Emma Shtivelman, PhD
New targeted and immunotherapy drugs have changed the diagnosis of metastatic melanoma from a death sentence into a disease that can potentially be managed and even cured. Nevertheless, these new drugs do not work in all patients, or they may stop working after a transient response. This post (part one of two) will describe ongoing efforts to find drug combinations with higher efficacy than single drugs and decipher the mechanisms underlying drug resistance.
February 8, 2016 Emma Shtivelman, PhD
About 10 months ago, we asked: is there a future for immunotherapy in breast cancer? Now, we can answer this question with a qualified “yes.” The data show why.